PETER MARLIN: Open Payments
NPI 1982694683 · COLORADO SPRINGS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,044 in 40 payments from 14 companies in 2025. Trend: 2023 $309 · 2024 $1,120 · 2025 $1,044
Food & beverage: $1,044
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 6 | $226 |
| E.R. Squibb & Sons, L.L.C. | 5 | $176 |
| Teva Pharmaceuticals USA, Inc. | 7 | $138 |
| Neurocrine BioSciences, Inc. | 3 | $104 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| ABBVIE INC. | 2 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Lundbeck LLC | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
Products named: ARISTADA, COBENFY, AUSTEDO XR, INGREZZA, REXULTI, VRAYLAR, CAPLYTA, VIVITROL.
Industry payments across CO — which companies pay providers there.
